Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,064.29
-23.09 (-2.12%)
Official Closing Price
Updated: 7:00 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation
January 15, 2026
In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx...
Via
MarketMinute
Topics
Intellectual Property
Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers
↗
January 15, 2026
Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive Specialties
Via
Benzinga
Topics
Lawsuit
Why Eli Lilly (LLY) Stock Is Down Today
January 15, 2026
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) delayed its decision on the company's new oral...
Via
StockStory
Topics
Artificial Intelligence
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers
↗
January 15, 2026
Via
Stocktwits
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly
↗
January 14, 2026
Via
Stocktwits
FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings
↗
January 13, 2026
Via
Stocktwits
What's going on in today's session: S&P500 movers
↗
January 15, 2026
Via
Chartmill
Thursday's session: gap up and gap down stock in the S&P500 index
↗
January 15, 2026
Via
Chartmill
The Silicon Laureates: How 2024’s ‘Nobel Prize Moment’ Rewrote the Laws of Scientific Discovery
January 14, 2026
The history of science is often measured in centuries, yet in October 2024, the timeline of human achievement underwent a tectonic shift that is only now being fully understood in early 2026. By...
Via
TokenRing AI
Topics
Artificial Intelligence
Electric Vehicles
Eli Lilly & Co (NYSE:LLY) Combines High Growth Momentum with a Strong Technical Setup
↗
January 13, 2026
Via
Chartmill
Behind the Scenes of Eli Lilly and Co's Latest Options Trends
↗
January 14, 2026
Via
Benzinga
The Digital Microscope: How AlphaFold 3 is Decoding the Molecular Language of Life
January 14, 2026
As of January 2026, the landscape of biological research has been irrevocably altered by the maturation of AlphaFold 3, the latest generative AI milestone from Alphabet Inc. (NASDAQ: GOOGL). Developed...
Via
TokenRing AI
Topics
Artificial Intelligence
Bonds
Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
↗
January 14, 2026
Retatrutide is an exciting GLP-1 drug that has explosive potential.
Via
The Motley Fool
Why Eli Lilly Stock Gained 39.2% In 2025
↗
January 14, 2026
The company is benefiting mightily from its portfolio of weight-loss drugs.
Via
The Motley Fool
Slimmer Waistlines, Fatter Margins: Jefferies Says Airline Companies Will Profit From America’s Weight-Loss Boom
↗
January 14, 2026
Via
Stocktwits
Healthcare Sector Stages Resilient Rebound as Policy Clarity and GLP-1 Innovations Fuel Investor Optimism
January 14, 2026
The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative...
Via
MarketMinute
Topics
Earnings
Economy
The Great Tariff-Inflation Tug-of-War: Why the Fed’s 2% Target Remains Elusive in 2026
January 14, 2026
As the United States enters the first quarter of 2026, the global economy is grappling with a radical shift in trade dynamics that has upended decades of globalization. The aggressive...
Via
MarketMinute
Topics
Economy
Supply Chain
World Trade
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
↗
January 14, 2026
Plenty of growth lies ahead for these top healthcare companies.
Via
The Motley Fool
A Fresh IPO That Long-Term Investors Shouldn’t Ignore
↗
January 14, 2026
Via
MarketBeat
Topics
Initial Public Offering
Is It Time to Dump Your Shares of Eli Lilly?
↗
January 14, 2026
What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?
Via
The Motley Fool
Topics
Intellectual Property
Jim Cramer Calls Nvidia, Eli Lilly Partnership 'Monumental Effort' To 'Speed Up' Critical Drug Creation
↗
January 14, 2026
Jim Cramer calls Nvidia-Eli Lilly partnership a "monumental effort" to speed up drug creation, despite Wall Street ignoring major AI shift.
Via
Benzinga
Topics
Artificial Intelligence
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
↗
January 13, 2026
Via
MarketBeat
Why This Fund Made a $72 Million Bet on a Stock Headed for a $210 Per Share Takeout
↗
January 13, 2026
Chart Industries delivers engineered cryogenic and heat transfer equipment to energy and industrial gas markets worldwide.
Via
The Motley Fool
Topics
Supply Chain
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
January 13, 2026
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
January 13, 2026
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...
Via
PredictStreet
Topics
Economy
Intellectual Property
Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds
↗
January 13, 2026
NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial intelligence across research, clinical trials, and supply chains over the next five...
Via
Benzinga
Topics
Artificial Intelligence
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?
↗
January 13, 2026
Both companies now aim to win in the oral weight loss drug market.
Via
The Motley Fool
Cooling Inflation Ignites Market Optimism: December CPI Report Paves Way for Fed Pivot
January 13, 2026
The Bureau of Labor Statistics released the December 2025 Consumer Price Index (CPI) report on the morning of January 13, 2026, revealing a headline inflation rate of 2.7%. While the headline figure...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Credit Cards
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?
↗
January 13, 2026
The gap may be too hard to close in the next 12 months.
Via
The Motley Fool
What to Expect From Eli Lilly’s Q4 2025 Earnings Report
January 13, 2026
Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.
Via
Barchart.com
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.